Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FT500 |
Synonyms | |
Therapy Description |
FT500 is a preparation of pluripotent cell line-derived natural-killer cells, which potentially increases T-cell recruitment to tumors, and may enhance anti-tumor immune response in combination with checkpoint inhibitors (Cancer Res 2018;78 (13 Suppl):Abstract nr 3576). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FT500 | FT-500|FT 500 | FT500 is a preparation of pluripotent cell line-derived natural-killer cells, which potentially increases T-cell recruitment to tumors, and may enhance anti-tumor immune response in combination with checkpoint inhibitors (Cancer Res 2018;78 (13 Suppl):Abstract nr 3576). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03841110 | Phase I | FT500 + Pembrolizumab Atezolizumab + FT500 FT500 + Nivolumab FT500 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | Completed | USA | 0 |